콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

35485

Supelco

2,4′-DDD

PESTANAL®, analytical standard

동의어(들):

1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane, (2,4′-Dichlorodiphenyl)dichloroethane, o,p′-DDD, Mitotane

로그인조직 및 계약 가격 보기


About This Item

Linear Formula:
(ClC6H4)2CHCHCl2
CAS Number:
Molecular Weight:
320.04
Beilstein:
2056007
EC Number:
UNSPSC 코드:
41116107
PubChem Substance ID:
NACRES:
NA.24

Grade

analytical standard

Quality Level

제품 라인

PESTANAL®

유통기한

limited shelf life, expiry date on the label

기술

HPLC: suitable
gas chromatography (GC): suitable

응용 분야

agriculture
environmental

형식

neat

SMILES string

ClC(Cl)C(c1ccc(Cl)cc1)c2ccccc2Cl

InChI

1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H

InChI key

JWBOIMRXGHLCPP-UHFFFAOYSA-N

유전자 정보

유사한 제품을 찾으십니까? 방문 제품 비교 안내

일반 설명

2,4′-DDD is generally used to reduce the endogenous CORT neuropeptide, which might mask the total population of intracellular corticosteroid receptors in sparrows. It is an adrenal specific agent, which can find potent applications in the treatment of adrenocortical carcinoma (ACC).

애플리케이션

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

법적 정보

PESTANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

픽토그램

Health hazard

신호어

Warning

유해 및 위험 성명서

Hazard Classifications

Carc. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable

개인 보호 장비

dust mask type N95 (US), Eyeshields, Gloves


가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

적합한 버전을 찾을 수 없으신가요?

특정 버전이 필요한 경우 로트 번호나 배치 번호로 특정 인증서를 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

이미 열람한 고객

Slide 1 of 1

1 of 1

Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients
Haak.R.H, et al.
British Journal of Cancer, 69(5), 947-951 (1994)
Pharmacological characterization of intracellular, membrane, and plasma binding sites for corticosterone in house sparrows
Breuner.WC and Orchinik M
General and Comparative Endocrinology, 163(1), 214-224 (2009)
Mitotane for adrenocortical carcinoma treatment
SH and MF
Current Opinion in Investigational Drugs, 6(4), 386-394 (2005)
Lawrence S Kirschner
Trends in endocrinology and metabolism: TEM, 23(7), 343-350 (2012-05-26)
Adrenocortical carcinoma (ACC) is a rare cancer for which few treatment options have been available. Currently, the best available treatment involves combination chemotherapy with the adrenolytic drug mitotane, although the response rate remains modest. Over the past 10 years there
Ilse G C Hermsen et al.
European journal of endocrinology, 169(1), 51-58 (2013-04-16)
Adrenocortical carcinoma (ACC) is a rare disease with a poor prognosis and limited therapeutic options. Mitotane is considered the standard first-line therapy with only 30% of the patients showing objective tumour response. Defining predictive factors for response is therefore of

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.